Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ATF4 | P18848 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2943580 | 1.00 | NPSR1 (0.40) | NPSR1TP53ALDH1A1POLBNAMPT | |
| SCHEMBL2947936 | 0.82 | NPSR1 (0.45) | NPSR1ALDH1A1POLBL3MBTL1SMN1; SMN2 | |
| SCHEMBL2947935 | 0.82 | NPSR1 (0.45) | NPSR1ALDH1A1POLBL3MBTL1SMN1; SMN2 | |
| SCHEMBL2944982 | 0.75 | L3MBTL1 (0.50) | NPSR1ALDH1A1POLBL3MBTL1SMN1; SMN2 | |
| SCHEMBL2944979 | 0.75 | L3MBTL1 (0.50) | NPSR1ALDH1A1POLBL3MBTL1SMN1; SMN2 | |
| SCHEMBL26106230 | 0.73 | POLB (0.46) | NPSR1TP53ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL26106226 | 0.73 | POLB (0.46) | NPSR1TP53ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL2078818 | 0.72 | TP53 (0.49) | NPSR1TP53ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL20293456 | 0.72 | TP53 (0.49) | NPSR1TP53ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL8076838 | 0.72 | TP53 (0.49) | NPSR1TP53ALDH1A1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737161-B2 | Condensed furan compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-06-15 | — | — | US | disclosed |
| EP-1489078-B1 | BENZOFURAN DERIVATIVE | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-01-06 | — | — | EP | disclosed |
| US-20090209511-A1 | Benzofuran Derivatives | KAWAGUCHI TAKAYUKI | 2009-08-20 | — | — | US | disclosed |
| US-20090156803-A1 | Condensed furan compounds | KAWAGUCHI TAKAYUKI | 2009-06-18 | — | — | US | disclosed |
| US-7531537-B2 | Benzofuran derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
| US-7514449-B2 | Fused furan compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-04-07 | — | — | US | disclosed |
| US-7375119-B2 | Amide type carboxamide derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-05-20 | — | — | US | disclosed |
| US-20060287329-A1 | Amide type carboxamide derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-12-21 | — | — | US | disclosed |
| EP-1666455-A1 | AMIDE TYPE CARBOXAMIDE DERIVATIVE | TANABE SEIYAKU CO., LTD. (JP) | 2006-06-07 | — | — | EP | disclosed |
| US-20060094724-A1 | Fused furan compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-05-04 | — | — | US | disclosed |
| US-20050282808-A1 | Benzofuran derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-12-22 | — | — | US | disclosed |
| EP-1582521-A1 | FUSED FURAN COMPOUND | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-05 | — | — | EP | disclosed |
| EP-1489078-A1 | BENZOFURAN DERIVATIVE | Tanabe Seiyaku Co., Ltd. (JP) | 2004-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282808-A1 | Benzofuran derivative | F12, F2, F11 | NPSR1 1260/4885TP53 4650/4885ALDH1A1 683/4885 |
| US-20060287329-A1 | Amide type carboxamide derivative | F12, F11, F13A1 | NPSR1 1754/4885TP53 4740/4885ALDH1A1 884/4885 |
| US-20090156803-A1 | Condensed furan compounds | F2, F12, F11 | NPSR1 2396/4885TP53 3379/4885ALDH1A1 1627/4885 |
| US-20090209511-A1 | Benzofuran Derivatives | F12, F2, F3 | NPSR1 1207/4885TP53 4644/4885ALDH1A1 693/4885 |
| US-20060094724-A1 | Fused furan compound | F2, F12, F11 | NPSR1 2530/4885TP53 3516/4885ALDH1A1 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.